Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib With or Without Vinorelbine in Advanced NSCLC
NCT04922658Phase 2Active, not recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Jun 2020
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in non-small cell lung cancer (NSCLC), sponsored by Cancer Center of Guangzhou Medical University. Started Jun 2020; status: active, not recruiting.
02
Drugs
surufatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04922658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922658.